MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jun 27, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MCNAIR Study is looking at the best ways to help patients with heart problems through cardiac rehabilitation, which is a program that includes exercise, education about heart health, and counseling. Many patients find it hard to attend in-person sessions, so this study is comparing in-person rehabilitation with telehealth, where patients can participate from home using technology. The goal is to find out if both methods are equally effective and whether some people benefit more from one approach than the other.
To join the study, you need to be at least 18 years old and have a heart condition that qualifies you for rehabilitation, such as a recent heart attack or heart failure. You also need to be comfortable communicating in English or Spanish and willing to be randomly assigned to either the in-person or telehealth program. If you decide to participate, you can expect support and guidance tailored to your needs, helping you improve your heart health in a way that works best for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 or older
- • 2. Eligible for cardiac rehabilitation
- • 1. Diagnosis within 1 year prior to consent
- • Myocardial infarction
- • Percutaneous coronary intervention
- • Coronary artery bypass
- • Heart valve repair or replacement
- • Heart transplant
- • 2. Chronic stable angina, or
- • 3. Chronic systolic heart failure (ejection fraction ≤ 35%)
- • 4. Referred to cardiac rehabilitation by a doctor or advanced practice provider for another indication that is covered by the participant's insurance, such as heart failure with preserved ejection fraction or aortic surgery.
- • 3. Willing to be randomized to in-person or telehealth cardiac rehabilitation
- • 4. Able to communicate in English or Spanish
- Exclusion Criteria:
- • 1. Unstable arrhythmias which may make unmonitored exercise unsafe (e.g., history of ventricular tachycardia not on medical therapy and without an implantable cardioverter defibrillator)
- • 2. Unsafe for patient to participate in the opinion of the investigator
- • 3. Hospice
- • 4. Unable to consent for self
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
San Francisco, California, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Alexis Beatty, MD, MAS
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported